Gastric cancer (GC) is a complex disease that represents the fifth most common malignancy in the world and the third leading cause of cancer death in both sexes. GC shows a high level of heterogeneity as well as a marked gender difference in incidence, GC affecting twice as many men as women. Chemotherapy (Ct) combined with surgery represents the standard of care for stages II-III GC, but the efficacy of such treatments is still limited for many patients. It is mandatory to develop novel therapeutic
...